Trial Profile

A Phase 1, Open-Label Study to Evaluate the Effect of AT-527 on the Pharmacokinetics of Digoxin in Healthy Adult Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 27 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bemnifosbuvir (Primary) ; Digoxin (Primary)
Indications COVID 2019 infections
Focus Pharmacokinetics
Sponsors Atea Pharmaceuticals

Most Recent Events

23 Feb 2023 Results from NCT05154123 and NCT05137626 presented in the Atea Pharmaceuticals Media Release.
22 Feb 2023 Results from two phase 1 studies(NCT05154123 and NCT05137626) assessing clinical implications of Bemnifosbuvi potential to inhibit P-gp, BCRP, and OATP1B1 mediated transport presented at the 30th Conference on Retroviruses and Opportunistic Infections 2023
23 Feb 2022 Status changed from not stated to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com